October 2021 Issue Table Of Contents

From The Editor

• Is Greed Good For Drug Development?

Feature Articles

• $4 Billion In 4 Years: The Story Of SpringWorks Therapeutics

CEO Corner

• Skills I Learned That Have Helped Me As A Public Pharma CEO

Companies To Watch

• Atea Pharmaceuticals

Industry Research

• Experience And Capacity’s Influence On Outsourcing

Inside The Industry

• Gearing Up For A Biotech M&A Boom
• Why It’s Never Too Early To Develop Your Exit Strategy
• How 3 Biopharma Entrepreneurs Responded To COVID-19 Lockdowns
• Do Strategic Partnerships Meet Outsourcers Expectations?
• Going Precommercial — From The Commercial World
• How Physicians Are Compensated By Life Sciences Companies
• How Quality Management Science Can Build A 5-Star Company
• How To Prepare For A Remote Regulatory Inspection
• From SPAC To De-SPAC, A Tutorial From A CFO
• Technology Changes Driving Life Sciences Industry Disruption

Leadership Lessons

• Why You Need “Uncomfortable Inclusion” In Business Today
• Become The Boss Of Burnout Syndrome

Ask The Board

• What Are Your Thoughts Around The Unprecedented Growth Of Biopharmas Going Public During The Pandemic?
• Do You Anticipate Attending The Annual J.P. Morgan Healthcare Conference In Person In January 2022?
• As A Mentor In Biopharma, What Is The One Piece Of Advice You Consistently Offer To Those You Mentor?